

# Inactivated SARS-CoV-2 vaccine VLA 2001 Project

11<sup>th</sup> of August, 2020

CONFIDENTIAL




# VLA2001 – SARS-CoV-2 inactivated vaccine

## Roadmap towards End 2021



△ Key Milestone

☆ Key Milestone achieved



\* Pending regulatory approval

Inactivated SARS-CoV-2 vaccine


CONFIDENTIAL

11th of August 2020

2

# VLA2001 – SARS-CoV-2 inactivated vaccine


## Supply planning



### VLA2001 – SARS-CoV-2 inactivated vaccine



Example of investments required to supply ~ (10)(1c)  
over 2021-2022



# VLA2001 – SARS-CoV-2 inactivated vaccine

## Cost structure



| CAPEX  | Pre-clinical  |
|--|---|
| (10)(1c)   | <ul style="list-style-type: none"><li>+ Pre-clinical<ul style="list-style-type: none"><li>› Studies in mice</li><li>› Studies in Non-Human Primates</li></ul></li></ul> |
| Commercial operations  | Clinical development  |
| <ul style="list-style-type: none"><li>+ Fixed costs<ul style="list-style-type: none"><li>› Employees</li><li>› Depreciations &amp; amortization</li></ul></li><li>+ Variable costs<ul style="list-style-type: none"><li>› Bill of Materials (BOM)</li><li>› Testing</li><li>› Energy</li></ul></li></ul> | (10)(1c)  |

## Proposal summary



| Volumes         | Funding         | Pricing & Payments terms |
|-----------------|-----------------|--------------------------|
| <p>(10)(1c)</p> | <p>(10)(1c)</p> | <p>(10)(1c)</p>          |

Thank you.

